88. 慢性血栓塞栓性肺高血圧症 Chronic thromboembolic pulmonary hypertension Clinical trials / Disease details
臨床試験数 : 157 / 薬物数 : 107 - (DrugBank : 22) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 54
Showing 1 to 10 of 157 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05140525 (ClinicalTrials.gov) | June 1, 2023 | 28/10/2021 | Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodyna ... | Effects of Combination Medical Therapy Followed by Balloon Pulmonary Angioplasty on Right Ventricular-PA Coupling and Hemodynamics in Chronic Thromboembolic Pulmonary Hypertension Effects of Combination Medical Therapy Followed by Balloon Pulmonary Angioplasty on Right Ventricula ... | CTEPH | Drug: Macitentan Tablets;Drug: Riociguat;Device: balloon pulmonary angioplasty | Dr Sudarshan Rajagopal | Actelion | Not yet recruiting | 18 Years | N/A | All | 15 | Phase 3 | United States |
2 | NCT05179356 (ClinicalTrials.gov) | January 1, 2023 | 16/12/2021 | Dapagliflozin in Pulmonary Arterial Hypertension | Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial Hypertension: A Double Blind Randomized Trial. (DAPAH-trial) Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial ... | Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension | Drug: Dapagliflozin 10 MG [Farxiga];Drug: Placebo | Mads Ersbøll | NULL | Not yet recruiting | 18 Years | N/A | All | 52 | Phase 2 | NULL |
3 | EUCTR2019-004131-24-PT (EUCTR) | 16/12/2022 | 25/08/2022 | A Phase 3 study to evaluate whether macitentan 75 mg is an effective and safe treatment for patients with inoperable or persistent chronic thromboembolic pulmonary hypertension. A Phase 3 study to evaluate whether macitentan 75 mg is an effective and safe treatment for patients ... | A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. Macitentan in inoperAble or persistent/reCurrent chronIc ThromboEmbolic Pulmonary Hypertension (MACiTEPH) - MACiTEPH A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive P ... | Chronic thromboembolic pulmonary hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Chronic thromboembolic pulmonary hypertension MedDRA version: 21.1;Level: PT;Classification code 100 ... | Trade Name: Opsumit® Product Name: Macitentan tablets Product Code: JNJ-67896062 / ACT-064992 INN or Proposed INN: MACITENTAN Other descriptive name: ACT-064992 Product Name: Macitentan tablets Product Code: JNJ-67896062 / ACT-064992 INN or Proposed INN: MACITENTAN Other descriptive name: ACT-064992 Product Name: Macitentan tablets Product Code: JNJ-67896062 / ACT-064992 INN or Proposed INN: MACITENTAN Other descriptive name: ACT-064992 Trade Name: Opsumit® Product Name: Macitentantablets Product Code: JNJ-67896062 / ACT-064992 INN or Pro ... | ACTELION Pharmaceuticals Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 230 | Phase 3 | Russian Federation;Singapore;United States;Czechia;Thailand;Portugal;Saudi Arabia;Austria;China;Korea, Republic of;Poland;Slovakia;France;Lithuania;Bulgaria;Serbia;Colombia;Argentina;Romania;Hungary;Japan;Ukraine;United Kingdom;Spain;Canada;Turkey;Taiwan;Denmark;Mexico;Italy;Israel;Australia;Germany Russian Federation;Singapore;United States;Czechia;Thailand;Portugal;Saudi Arabia;Austria;China;Kore ... | ||
4 | NCT05340023 (ClinicalTrials.gov) | November 9, 2022 | 17/11/2021 | Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension | Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension : PROTEO-CTEPH Study. Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension: PR ... | Chronic Thromboembolic Pulmonary Hypertension | Biological: blood sample | Centre Hospitalier Universitaire de Saint Etienne | NULL | Recruiting | 18 Years | N/A | All | 120 | France | |
5 | EUCTR2021-006787-25-DK (EUCTR) | 06/07/2022 | 22/12/2021 | The effects of dapagliflozin in patients with elevated blood pressure in the lungs | Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial ... | Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 21.1;Classification code 10065151;Term: Idiopathic pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 24.1;Classification code 10085244;Term: Heritable pulmonary arterial hypertension;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 21.0;Classification code 10068740;Term: CTEPH;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension MedDRA version: 21.1;Le ... | Trade Name: Forxiga (dapagliflozin) Product Name: Forxiga INN or Proposed INN: Dapagliflozin | Rigshospitalet The Heart Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 52 | Phase 2 | Denmark | ||
6 | JPRN-jRCT2051220042 | 07/06/2022 | 09/06/2022 | Clinical trial of Nitric Oxide inhalation therapy in patients with severe PH | A Single-Center, Randomised, Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide therapy in the patients with severe right heart failure due to pulmonary hypertension A Single-Center, Randomised, Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide the ... | Pulmonary arterial hypertension (PAH), and Chronic thromboembolic pulmonary hypertension (CTEPH) PH, Nitric oxide, PAH, CTEPH, Right heart failure;D006976 Pulmonary arterial hypertension (PAH), and Chronic thromboembolic pulmonary hypertension(CTEPH) PH, ... | Study drug: Nitric Oxide (INOflo for inhalation 800ppm) Start inhalation at a concentration of 20 ppm, and if the blood methemoglobin concentration is below 2%, increase the dose by 10 ppm every 5 minutes to a maximum concentration of 40 ppm. On withdrawal from inhalation, if hemodynamics and oxygenation are stable, reduce inhalation dose by half every 5 minutes, gradually decreasing to 5 ppm. And then, If hemodynamics and oxygenation are stable at 1 ppm, attempt inhalation withdrawal every 5 minutes. Study drug: Nitric Oxide(INOflo for inhalation 800ppm) Start inhalation at a concentration of 20 ppm, ... | Ogo Takeshi | NULL | Pending | >= 18age old | Not applicable | Both | 30 | Phase 2 | Japan |
7 | NCT04954742 (ClinicalTrials.gov) | April 13, 2022 | 29/6/2021 | Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH | An Open-label, Prospective, Single Centre Study of the Effects of Riociguat on RIght VEntricular Size and Function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension An Open-label, Prospective, Single Centre Study of the Effects of Riociguat on RIght VEntricular Siz ... | Primary Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension | Drug: Riociguat | Heidelberg University | Merck Sharp & Dohme Corp. | Recruiting | 18 Years | N/A | All | 30 | Phase 4 | Germany |
8 | NCT05133713 (ClinicalTrials.gov) | April 1, 2022 | 1/11/2021 | Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus ... | Ventilation and Perfusion Imaging in Acute Pulmonary Embolism Following Catheter Directed Aspiration Thrombectomy Versus Conservative Therapy Alone: A Pilot Study Ventilation and Perfusion Imaging in Acute Pulmonary Embolism Following Catheter Directed Aspiration ... | Pulmonary Embolism;Pulmonary Hypertension;Chronic Thromboembolic Pulmonary Hypertension | Device: Catheter directed therapy;Drug: Systemic anticoagulation | University of Arizona | Inari Medical | Recruiting | 18 Years | N/A | All | 50 | United States | |
9 | ChiCTR2100052570 | 2021-08-01 | 2021-10-31 | A randomized controlled study of the effectiveness of percutaneous pulmonary thrombotic tissue aspiration in improving pulmonary blood flow grading in patients with chronic thromboembolic pulmonary hypertension A randomized controlled study of the effectiveness of percutaneous pulmonary thrombotic tissue aspir ... | A randomized controlled study of the effectiveness of percutaneous pulmonary thrombotic tissue aspiration in improving pulmonary blood flow grading in patients with chronic thromboembolic pulmonary hypertension A randomized controlled study of the effectiveness of percutaneous pulmonary thrombotic tissue aspir ... | Chronic Thromboembolic Pulmonary Hypertension | Control group:Traditional simple BPA procedure;Experimental group:Traditional simple BPA + thrombotic tissue removal; Control group:Traditional simple BPAprocedure;Experimental group:Traditional simple BPA+ thrombotic ... | Fuwai Hospital, Chinese Academy of Medical Sciences | NULL | Recruiting | 18 | 80 | Both | Control group:20;Experimental group:20; | China | |
10 | JPRN-jRCT2051200150 | 12/07/2021 | 11/03/2021 | A study to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension A study to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent ch ... | A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive P ... | Chronic thromboembolic pulmonary hypertension | Macitentan Participant will receive macitentan at a dose of 10 milligram (mg) once daily (OD) for 4 weeks, followed by a dose of macitentan 37.5 mg for another 4 weeks and continue with the target dose of macitentan 75 mg. Participants who have reached the target dose of 75 mg, completed the Double-blind (DB) period up to Week 28 (either on treatment or in Post-treatment observation period [PTOP]) at minimum, may be eligible for transitioning into the Open label (OL) extension period once all participants have completed the DB part of the study, or earlier if they experienced a Clinical event committee (CEC) confirmed clinical worsening event. Placebo Participants will receive placebo tablets matching the macitentan 10 mg, macitentan 37.5mg and macitentan 75 mg tablets, respectively. Participants who completed the DB period as per protocol either on treatment or in PTOP are eligible for transitioning to the OL extension period and will receive macitentan 75 mg after an 8-week double-dummy uptitration (macitentan 10 mg for 4 weeks, followed by 37.5 mg for another 4 weeks). Macitentan Participant will receive macitentanat a dose of 10 milligram (mg) once daily (OD) for 4 we ... | Nakano Masayoshi | NULL | Recruiting | >= 18age old | <= 80age old | Both | 144 | Phase 3 | USA;Germany;Hungary;South Korea;Japan |